Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT

Prostate. 2017 Aug;77(11):1205-1212. doi: 10.1002/pros.23379. Epub 2017 Jun 26.

Abstract

Background: Emerging data from published studies are demonstrating the superiority of Ga-68 PSMA PET/CT imaging in prostate cancer. However, the low yield of the Ge-68/Ga-68 from which Gallium-68 is obtained and fewer installed PET/CT systems compared to the SPECT imaging systems may limit its availability. We, therefore, evaluated in a head-to-head comparison, the diagnostic sensitivity of Ga-68 PSMA PET/CT and Tc-99m PSMA SPECT/CT in patients with prostate cancer.

Methods: A total of 14 patients with histologically confirmed prostate cancer were prospectively recruited to undergo Ga-68 PSMA PET/CT and Tc-99m HYNIC PSMA SPECT/CT. The mean age of patients was 67.21 ± 8.15 years and the median PSA level was 45.18 ng/mL (range = 1.51-687 ng/mL). SUVmax of all lesions and the size of lymph nodes with PSMA avidity on Ga-68 PSMA PET/CT were determined. Proportions of these lesions detected on Tc-99m HYNIC PSMA SPECT/CT read independent of PET/CT findings were determined.

Results: A total of 46 lesions were seen on Ga-68 PSMA PET/CT localized to the prostate (n = 10), lymph nodes (n = 24), and bones (n = 12). Of these, Tc-99m HYNIC PSMA SPECT/CT detected 36 lesions: Prostate = 10/10 (100%), lymph nodes = 15/24 (62.5%), and bones = 11/12 (91.7%) with an overall sensitivity of 78.3%. Lesions detected on Tc-99m HYNIC PSMA SPECT/CT were bigger in size (P < 0.001) and had higher SUVmax (P < 0.001) as measured on Ga-68 PSMA PET/CT compared to those lesions that were not detected. All lymph nodes greater than 10 mm in size were detected while only 28% of nodes less than 10 mm were detected by Tc-99m HYNIC PSMA SPECT/CT. In a univariate analysis, Lymph node size (P = 0.033) and the SUVmax of all lesions (P = 0.007) were significant predictors of lesion detection on Tc-99m HYNIC PSMA SPECT/CT.

Conclusion: Tc-99m HYNIC PSMA may be a useful in imaging of prostate cancer although with a lower sensitivity for lesion detection compared to Ga-68 PSMA PET/CT. Its use is recommended when Ga-68 PSMA is not readily available, in planning radio-guided surgery or the patient is being considered for radio-ligand therapy with Lu-177 PSMA. It performs poorly in detecting small-sized lesions hence its use is not recommended in patients with small volume disease.

Keywords: PET/CT; PSMA; SPECT/CT; Tc-99m; prostate cancer.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens, Surface / administration & dosage
  • Gallium Radioisotopes / administration & dosage
  • Gallium Radioisotopes / standards*
  • Glutamate Carboxypeptidase II / administration & dosage
  • Glutamate Carboxypeptidase II / standards*
  • Humans
  • Hydrazines / administration & dosage
  • Hydrazines / standards*
  • Male
  • Middle Aged
  • Nicotinic Acids / administration & dosage
  • Nicotinic Acids / standards*
  • Positron Emission Tomography Computed Tomography / methods
  • Positron Emission Tomography Computed Tomography / standards*
  • Prospective Studies
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / metabolism
  • Single Photon Emission Computed Tomography Computed Tomography / methods
  • Single Photon Emission Computed Tomography Computed Tomography / standards*
  • Technetium / administration & dosage
  • Technetium / standards*

Substances

  • 6-hydrazinopyridine-3-carboxylic acid
  • Antigens, Surface
  • Gallium Radioisotopes
  • Hydrazines
  • Nicotinic Acids
  • Technetium
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II